A STUDY TO EVALUATE THE EFFECT OF LONG-TERM TREATMENT WITH BELVIQ (LORCASERIN HCL) ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND CONVERSION TO TYPE 2 DIABETES MELLITUS IN OBESE AND OVERWEIGHT SUBJECTS WITH CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS: